We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Sanofi has entered an agreement with MSD – known as Merck & Co in the US – to collaborate on a phase II trial evaluating its investigational candidate THOR-707 alongside MSD’s immunotherapy Keytruda.
French pharmaceutical company Sanofi has agreed to acquire all outstanding shares of biotechnology firm Synthorx for a total consideration of $2.5bn, or $68 per share in cash.